Stock 1799 EASYWELL BIOMEDICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Easywell Biomedicals, Inc.

Equities

1799

TW0001799005

Pharmaceuticals

End-of-day quote Taipei Exchange
Other stock markets
 18:00:00 2024-05-12 EDT 		5-day change 1st Jan Change
74 TWD -3.27% Intraday chart for Easywell Biomedicals, Inc. +0.68% +79.18%
05-08 Easywell Biomedicals, Inc. announced a financing transaction CI
04-07 Easywell Biomedicals, Inc.'s Subsidiary Jiangsu Huahan Pharma-Tech Co., Ltd. Obtains Approval from the Jiangsu Medical Products Administration of China for Compliance with the Good Manufacturing Practice Inspection for Pharmaceuticals CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,087 1,243 2,418 2,598 1,836 4,785
Enterprise Value (EV) 1 977.8 1,432 2,504 2,484 1,846 4,824
P/E ratio -4.49 x -3.98 x -13.3 x -16.1 x -11.4 x -32.6 x
Yield - - - - - -
Capitalization / Revenue 2.59 x 3.45 x 9.03 x 13.2 x 10.3 x 17.6 x
EV / Revenue 2.33 x 3.98 x 9.35 x 12.6 x 10.3 x 17.8 x
EV / EBITDA -5.92 x -9.6 x -26 x -15.5 x -15.9 x -39.9 x
EV / FCF -3.87 x -23.6 x -47.9 x -31.2 x -65.3 x -40.9 x
FCF Yield -25.8% -4.24% -2.09% -3.2% -1.53% -2.44%
Price to Book 1.52 x 1.84 x 3.44 x 2.97 x 2.49 x 7.81 x
Nbr of stocks (in thousands) 69,190 88,090 97,566 114,366 114,366 115,866
Reference price 2 15.71 14.11 24.79 22.71 16.05 41.30
Announcement Date 19-03-28 20-03-30 21-03-30 22-03-31 24-03-28 24-03-28
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 419.2 360 267.7 197.3 178.9 271.6
EBITDA 1 -165.2 -149.1 -96.31 -160.4 -116 -121
EBIT 1 -235.6 -216 -158.9 -211.9 -161.3 -162.7
Operating Margin -56.2% -60% -59.35% -107.39% -90.14% -59.91%
Earnings before Tax (EBT) 1 -335.3 -268.2 -182.8 -169.7 -168.3 -169.9
Net income 1 -242.2 -271.8 -173.4 -150.4 -161 -144.8
Net margin -57.77% -75.51% -64.79% -76.23% -90% -53.31%
EPS 2 -3.500 -3.549 -1.859 -1.413 -1.408 -1.266
Free Cash Flow 1 -252.7 -60.71 -52.22 -79.6 -28.28 -117.9
FCF margin -60.28% -16.87% -19.51% -40.35% -15.81% -43.39%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 19-03-28 20-03-30 21-03-30 22-03-31 24-03-28 24-03-28
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 189 85.4 - 10.4 38.3
Net Cash position 1 109 - - 114 - -
Leverage (Debt/EBITDA) - -1.265 x -0.8862 x - -0.0898 x -0.3166 x
Free Cash Flow 1 -253 -60.7 -52.2 -79.6 -28.3 -118
ROE (net income / shareholders' equity) -33.6% -36.1% -25.3% -20.4% -20% -24.4%
ROA (Net income/ Total Assets) -12.6% -12.4% -8.7% -11.2% -8.27% -8.52%
Assets 1 1,930 2,196 1,992 1,347 1,947 1,699
Book Value Per Share 2 10.40 7.690 7.220 7.640 6.460 5.290
Cash Flow per Share 2 3.030 2.690 1.490 1.340 1.390 2.270
Capex 1 118 21.7 17 7.71 7.49 17.7
Capex / Sales 28.04% 6.03% 6.34% 3.91% 4.19% 6.53%
Announcement Date 19-03-28 20-03-30 21-03-30 22-03-31 24-03-28 24-03-28
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
EASYWELL BIOMEDICALS, INC. Stock Easywell Biomedicals, Inc.
+79.18% 278M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.98% 682B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.54% 586B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.52% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.59% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.07% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.74% 240B
NOVARTIS AG Stock Novartis AG
+9.71% 209B
ROCHE HOLDING AG Stock Roche Holding AG
-8.55% 203B
AMGEN INC. Stock Amgen Inc.
+7.09% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 1799 Stock
  4. Financials Easywell Biomedicals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW